Compare Novo Nordisk A/S (NVO) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs OneSpan Inc — how do they compare? Novo Nordisk A/S trades at $46.44 (market cap $207.85B), while OneSpan Inc trades at $16.57 (market cap $600.69M). The key difference: Novo Nordisk A/S is far larger — about 346× OneSpan Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | OSPN | |
|---|---|---|
Market Cap | $207.85B | $600.69M |
Sector | Health | Technology |
52-Week High | $63.98 | $16.78 |
52-Week Low | $35.29 | $10.15 |
Enterprise Value | $222.55B | $569.77M |
Dividend Yield | 3.81% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
OneSpan (OSPN) trades at $16.53, up 0.98% in the last session, with a bullish technical signal from moving averages. The stock shows strong profitability with a net income margin of 27.76% and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and the launch of DigipassONE, supporting growth in subscription revenue.
Outlook remains positive with a consensus price target of $17.00, though risks include declining net cash flow and competitive pressures. The stock offers value with a P/E of 9.21, but investors should monitor execution on guidance and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
